Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study.

Literature DB >> 31090915

Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study.

Maria-Victoria Mateos¹, Robert Z Orlowski², Enrique M Ocio³, Paula Rodríguez-Otero⁴, Donna Reece⁵, Philippe Moreau⁶, Nikhil Munshi⁷, David E Avigan⁸, David S Siegel⁹, Razi Ghori¹⁰, Mohammed Z H Farooqui¹⁰, Patricia Marinello¹⁰, Jesus San-Miguel⁴.

Abstract

Entities: Chemical Disease

Keywords: dexamethasone; lenalidomide; multiple myeloma; pembrolizumab; relapsed/refractory

Year: 2019 PMID： 31090915 DOI： 10.1111/bjh.15946

Source DB: PubMed Journal: Br J Haematol ISSN： 0007-1048 Impact factor: 6.998

Keyword Cloud
Cited

× No keyword cloud information.

20 in total

Review 1. Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm.

Authors: Alana L Keller; Daniel W Sherbenou; Peter A Forsberg; Tomer M Mark
Journal: Front Oncol Date: 2022-06-24 Impact factor: 5.738

Review 2. How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma.

Authors: Adam D Cohen; Noopur Raje; Jessica A Fowler; Khalid Mezzi; Emma C Scott; Madhav V Dhodapkar
Journal: Clin Cancer Res Date: 2019-10-31 Impact factor: 12.531

3. Checkpoint inhibitors and myeloma: promises, deadlocks and new directions.

Authors: Luca Bertamini; Francesca Gay
Journal: Ann Transl Med Date: 2020-06

Review 4. Immunotherapy for Multiple Myeloma.

Authors: Hideto Tamura; Mariko Ishibashi; Mika Sunakawa; Koiti Inokuchi
Journal: Cancers (Basel) Date: 2019-12-12 Impact factor: 6.639

Review 5. Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True.

Authors: Mattia D'Agostino; Salvatore Innorcia; Mario Boccadoro; Sara Bringhen
Journal: Int J Mol Sci Date: 2020-11-01 Impact factor: 5.923

Review 6. Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy.

Authors: Helmi Alfarra; Jackson Weir; Stacy Grieve; Tony Reiman
Journal: Front Immunol Date: 2020-11-12 Impact factor: 7.561

7. V-Domain Ig Suppressor of T Cell Activation (VISTA) Expression Is an Independent Prognostic Factor in Multiple Myeloma.

Authors: Pim Mutsaers; Hayri E Balcioglu; Rowan Kuiper; Dora Hammerl; Rebecca Wijers; Mark van Duin; Bronno van der Holt; Annemiek Broijl; Walter Gregory; Sonja Zweegman; Pieter Sonneveld; Reno Debets
Journal: Cancers (Basel) Date: 2021-05-06 Impact factor: 6.639